Tisotumab vedotin

维替索妥尤单抗

Report date: 2026/04/15 20:02:38
First In Class

Base Information

Drug NameTisotumab vedotin
Drug Alias Name维汀-替索妥单抗HuMax-TF-ADC维替索妥人单抗tisotumab vedotinatisotumabum vedotinum +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsTissue factor inhibitors
TargetsTissue factorTubulin
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[14] 
Global Approved IndicationsUterine Cervical Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/09/20
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesSeagen IncZai Lab LtdGenmab A/S +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Inactive IndicationsUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[5] 

Other Information

ATC CodeL01XC
Related LinksDrugBankKEGG